IPO Boutique

Nabriva Therapeutics AG IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Nabriva Therapeutics AG, and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Nabriva Therapeutics AGNBRV -
NASDAQ
$10.50-$10.50 $10.25 $11.399 million9/18/2015
Leerink Partners, RBC Capital Markets
Co-Manager(s):
Needham & Company, Wedbush PacGrow
Health Care
Filing(s):

Filed 2015-06-18
Terms Added 2015-09-08
Amended Terms 2015-09-17



Nabriva Therapeutics AG Quote & Chart - Click for current quote - NBRV

About Nabriva Therapeutics AG (adapted from Nabriva Therapeutics AG prospectus):
They are a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "NBRV" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved